tbuckley/cabot-search huggingface dataset:
Effect of a gastrointestinal multidisciplinary clinic on the quality of pancreatic cancer care delivery at a community cancer center.
Authors: Laurence E. McCahill, Gerald P. Wright, Sunil Konduri, Mary May, Coralyn Martinez, Wendy K. Taylor, J. Brad Morrow, Alan T. Davis
Journal: Journal of Clinical Oncology (2012)

378 Background: Healthcare reform calls for measurements of value in services received. The 2002 IOM report Crossing the Quality Chasm emphasized deficits in efficiency, effectiveness, and patient centeredness. In 2009, a pancreatic cancer panel proposed 43 measures for high quality pancreatic cancer care. We incorporated these composite measures into a unique program of multidisciplinary (MD) care, nurse navigation (NN), and quality monitoring. Methods: A MD gastrointestinal cancer program was initiated in Jan 2010. Key components included a treatment planning conference followed immediately by a MD clinic. A GI NN coordinated staging, clinical evaluation, and treatment initiation. Patients with suspected /newly diagnosed pancreatic or periampullary neoplasms were included. We evaluated our quality of cancer care and outcomes proposed by the pancreatic cancer quality expert panel. Results: A total of 76 patients with pancreatic neoplasms were evaluated over 18 months, 55 subjects had confirmed malignancies. Of these, 20 were clinical Stage I/II, 15 stage III and 20 Stage IV. Quality measures in Table 1 focus on quality measures. 25 patients underwent resection. Mean OR time was 424 min, mean EBL 843 mL, morbidity 30%, mortality 4%, R0 resection rate 76%, mean nodes evaluated 24, and mean hospital LOS 10 days. Complete adherence with guidelines occurred in all 30 non-operative patients and 22 of 25 patients who undergoing resection. Overall compliance for all pancreatic cancer care guidelines was 99.7%. Conclusions: Comprehensive MD pancreatic cancer evaluation and care is feasible in a community cancer. We believe this study establishes new benchmarks of quality and value assessment for pancreatic cancer programs. [Table: see text]
Distinct Proteomic Signaling Networks Stratify Responses to Ara-C Based Induction Therapy in Patients with Acute Myeloid Leukemia (AML)
Authors: Mark Minden, David Rosen, Santosh Putta, Aileen Cohen, Helen Francis-Lang, Todd Covey, John Woronicz, David Soper, Brian Long, James Cordeiro, Lootsie Panganiban-Lustan, Steve Banville, Urte Gayko, Alessandra Cesano, Wendy Fantl
Journal: Blood (2008)
Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort study
Authors: Alyshah Abdul Sultan, Joe West, Matthew J Grainge, Richard D Riley, Laila J Tata, Olof Stephansson, Kate M Fleming, Catherine Nelson-Piercy, Jonas F Ludvigsson
Journal: BMJ (2016)

To develop and validate a risk prediction model for venous thromboembolism in the first six weeks after delivery (early postpartum). Cohort study. Records from England based Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES) and data from Sweden based registry. All pregnant women registered with CPRD-HES linked data between 1997 and 2014 and Swedish medical birth registry between 2005 and 2011 with postpartum follow-up. Multivariable logistic regression analysis was used to develop a risk prediction model for postpartum venous thromboembolism based on the English data, which was externally validated in the Swedish data. 433 353 deliveries were identified in the English cohort and 662 387 in the Swedish cohort. The absolute rate of venous thromboembolism was 7.2 per 10 000 deliveries in the English cohort and 7.9 per 10 000 in the Swedish cohort. Emergency caesarean delivery, stillbirth, varicose veins, pre-eclampsia/eclampsia, postpartum infection, and comorbidities were the strongest predictors of venous thromboembolism in the final multivariable model. Discrimination of the model was similar in both cohorts, with a C statistic above 0.70, with excellent calibration of observed and predicted risks. The model identified more venous thromboembolism events than the existing national English (sensitivity 68% v 63%) and Swedish guidelines (30% v 21%) at similar thresholds. A new prediction model that quantifies absolute risk of postpartum venous thromboembolism has been developed and externally validated. It is based on clinical variables that are available in many developed countries at the point of delivery and could serve as the basis for real time decisions on obstetric thromboprophylaxis.
Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP)
Authors: E.A.M. van der Voort, M. Wakkee, P. Veldt-Kok, S. Darwish Murad, T. Nijsten
Journal: British Journal of Dermatology (2016)

The enhanced liver fibrosis (ELF) test has been introduced to screen, diagnose and/or monitor liver conditions in large groups of patients with liver diseases. It has not been used in inflammatory skin or joint diseases. To evaluate the distribution of the ELF test, apply existing cut‐offs for hepatic patients and healthy controls, and compare it with the procollagen‐3 N‐terminal peptide (P3NP) test in patients with psoriasis (PSO), psoriatic arthritis (PsA) and rheumatoid arthritis (RA), and controls. In total, 531 patients were included. Demographic, lifestyle and disease‐specific data were collected. ELF and P3NP tests were performed. Prevalence of an increased ELF score (> 11) and P3NP was highest in patients with RA (7·7% and 6·1%, respectively) followed by patients with PSO (1·7% and 5·2%, respectively) and PsA (0·7% and 1·3%, respectively). Mean ± SD ELF scores for PSO, PsA and RA were, respectively, 9·09 ± 0·86, 8·96 ± 0·76 and 9·55 ± 1·04. All subgroups with moderate‐to‐severe disease severity had higher (> 9·8) ELF scores (PSO 27·0% vs. 18·3%; PsA 19·2% vs. 12%; RA 45·8% vs. 30·5%) and P3NP values. Distribution of the ELF score was smaller than the P3NP value [mean ± SD: 9·15 ± 0·92 (range 6·53–13·05) vs. 8·37 ± 4·30 (range 0·53–63·88)]. ELF score and P3NP are elevated in PSO, PsA and RA. ELF may be superior to P3NP alone, but further research should be done to validate the ELF test in determining susceptibility for developing liver fibrosis in PSO, PsA and RA.
Topoisomerase II alpha (TopoIIa) and MAPtau: Potential predictive markers of response in locally advanced breast cancer (LABC) treated with epirubicin and docetaxel (ET) in neoadjuvant setting.
Authors: A. Cristofano, A. Inno, V. Arena, L. Nicosia, G. Jocollè, M. Campitiello, P. Carassai, C. Pozzo, G. Numico, C. Barone
Journal: Journal of Clinical Oncology (2011)

57 Background: Neoadjuvant chemotherapy can achieve a high objective response rate in patients with LABC. This allows breast conservation surgery in those patients who are initially not suitable for this procedure. The patients who mainly benefit from neoadjuvant chemotherapy are those who achieve a pathological complete response (pCR) with no residual microscopic tumour. This occurs in only 3–16% of patients, who have substantially improved disease-free survival (DFS) and OS compared to those with pathological evidence of residual cancer. In order to identify patients most likely to achieve benefit from neoadjuvant chemotherapy, it would be useful to identify predictors of pCR. ET is a valid doublet therapy in the neoadjuvant setting; Topo-IIa and MAP-Tau are the principal targets of anthracyclines and taxanes, respectively. We evaluated a possible role of the two proteins in predicting a pathological response rate in LABC. Methods: TopoIIa and MAPtau expression was evaluated by immunohistochemistry (IHC) in tumour biopsy from 22 women with LABC treated with ET as neoadjuvant chemotherapy, and protein levels were correlated to the outcome. Results: TopoIIa over-expression was significantly associated with ductal histology (58.3% in ductal carcinoma vs 0% in other hystotypes, p=.038) and hormone receptors (HRs) expression (63.6% in HR+ vs 0% in HR- tumours), whereas no significant correlation was observed with HER2 expression. MAP-tau did not correlate with histology, grading, HRs and HER2 status. Pathological complete response (pCR) rate was higher in tumours with MAPtau low/normal expression compare to those over-expressing the protein (36.4% vs. 14.3%), although not significantly. Pts with TopoIIa over-expression achieved a significantly higher pCR rate than those with a low/normal expression (57.1% vs. 9.1%; p=.047). Data on the RFS are not available because of the short period of follow-up. Conclusions: IHC evaluation of TopoIIa might be useful in identifying pts potentially responsive to neoadjuvant chemotherapy with anthracyclines and taxanes. Data on RFS will be available later.
C11-acetate PET for docetaxel prednisone (DP) response assessment in castrate-resistant prostate cancer (CRPC).
Authors: Nancy Sharma, Yusuf Menda, Laura Boles-Ponto, Daniel A. Vaena
Journal: Journal of Clinical Oncology (2012)

e15143 Background: C11- acetate (acetate) positron-emission tomogram (PET) has shown promise in detection of metastasis in prostate cancer in recent studies. Our study tested the feasibility of acetate-PET to predict early response to DP in CRPC. Methods: Men with metastatic CRPC for whom DP was indicated were enrolled in a prospective study of acetate-PET imaging and bone scans. Patients (pts) were imaged with both modalities at study entry and after 3 cycles of DP. DP was continued beyond cycle 3 until PCWG2-defined progression or toxicity. Treating physicians were blinded to acetate-PET results. No pts were on statins. The study was IRB-approved. Results: 6 pts with documented bone metastases were imaged (5 both pre and post-therapy.) Pre-therapy acetate-PET identified osseous metastases in all 6 pts. Remarkably, in one pt with previous radiation therapy, pre-therapy acetate-PET was negative for disease in the radiated area whereas bone scan showed persistent activity. The median number of DP cycles was 7 (5-16). 4 pts had ≥ 50% PSA decline. The median time to progression (TTP) was 5 months (mo). Of the 4 pts with PSA response, 2 had response on acetate-PET with TTP 5 mo and 10 mo respectively. One pt had &gt; 50% PSA response but progression after 3 cycles based on PET, and met PCWG2 criteria for progression at 3.5 mo. The 4 th pt with PSA response had stable findings on post-therapy PET and had 13 mo TTP. The pt who had no PSA response had stable post-therapy PET and had 2 mo TTP. Bone scan was stable in 3 pts, showed progression in 1pt and showed response in 1 pt. Conclusions: Response or progression on acetate-PET can be seen after a few chemotherapy cycles for CRPC. This study supports the exploratory inclusion of acetate-PET in future therapeutic clinical trials, with the potential to enhance the early prediction of treatment outcome. Acetate-PET might also allow more precise identification of viable target lesions than bone scan.
Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation
Authors: Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. Le Coutre, Charles Chuah, Franck E Nicolini, Ron Paquette, Jane F Apperley, John F. DiPersio, H. Jean Khoury, Delphine Rea, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Michele Baccarani, Martin C Mueller, Carlo Gambacorti-Passerini, Stephane Wong, Stephanie Lustgarten, Christopher D. Turner, Victor M. Rivera, Tim Clackson, Frank Haluska, Hagop M. Kantarjian
Journal: Blood (2011)
Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt
Authors: Rashid Z Khan, Christoph Heuck, Adam Rosenthal, Caleb K Stein, Joshua Epstein, Shmuel Yaccoby, Xenofon Papanikolaou, Yogesh Jethava, Maurizio Zangari, Frits Van Rhee, Madhav V. Dhodapkar, Gareth J Morgan, Antje Hoering, John Crowley, Bart Barlogie
Journal: Blood (2014)
Chemotherapy in advanced pleomorphic sarcomas: The experience of the Royal Marsden Hospital (RMH).
Authors: E. Thanopoulou, C. Benson, O. Al-Muderis, C. Fisher, C. Propert-Lewis, A. Dunlop, I. R. Judson, M. Scurr
Journal: Journal of Clinical Oncology (2011)

e20510 Background: The 2002 WHO classification redefined malignant fibrous histiocytoma as “undifferentiated pleomorphic sarcoma (PSa)”. There is little data regarding clinical outcomes and responses to chemotherapy for PSa; thus a review of patients (pts) treated with chemotherapy (CT) at the RMH was undertaken. Methods: All pts with histologically confirmed PSa who received CT between January 2005 and January 2011 were identified from the prospectively maintained database of the Sarcoma Unit. Data collection included demographics, CT type, duration and clinical outcomes (clinical benefit rate-CBR (CR+PR+SD), progression free survival (PFS) and overall survival (OS). A preliminary analysis for outcome utilising the RMH prognostic score (albumin, number (No) of metastases, and LDH) was undertaken to define those likely to benefit. Results: Twenty four pts received CT in the advanced setting. Median age was 58yrs (27-71) and male: female ratio was 13:11. At initial presentation all but one had had localised disease treated with surgery±radiotherapy. Of these, 3 relapsed locally and 20 had metastatic disease. Median disease free survival was 6 months (mo) (1-32). First line CT comprised single agent doxorubicin (Dox) in 17 pts, ifosfamide (IFO) + Dox in 6 pts and single agent IFO in 1 pt. The CBR was 30% for Dox (4 PR, 1SD) and 67% for IFO+Dox (1 CR, 1PR, 2SD). The pt on IFO alone achieved PR. The median No of cycles was 2 (1-6) for Dox and 6 (1-6) for IFO+Dox. The median PFS for Dox was 2 mo (1-42+) and 6.5 mo (1-25+) for IFO+Dox. Out of 10 pts receiving second line CT, 9 pts had IFO. Two pts achieved SD. PFS for second line CT was 2 mo (1-3). The OS from time of relapse was 8.6 mo (1.5- 51.1). In this small cohort of pts a correlation was seen between the RMH prognostic score and outcome. Conclusions: The outcome for pts with metastatic PSa is poor. Whilst there is reasonable activity to single agent Dox, there would appear to be a survival advantage to the combination in this subgroup and should be considered in those fit enough. The correlation between the RMH prognostic score and outcomes in this group of pts is intriguing and prospective evaluation in this and other sarcoma subtypes is warranted.
Overcoming chemotherapy resistance in patients (pts) with chemotherapy-failure, castration-resistant prostate cancer (CRPC) with sorafenib.
Authors: Chadi Nabhan, Peter Hubert Cygan, Andrew Meyer, Kathy Tolzien, Angel G. Galvez, Timothy M. Lestingi, Jacob D. Bitran
Journal: Journal of Clinical Oncology (2012)

127 Background: SOR is an oral multi kinase inhibitor that promotes apoptosis through downstream pathways that can be deregulated in CRPC leading to chemotherapy resistance. We hypothesized that SOR Could overcome chemotherapy resistance in non-responders or in those who progress shortly after stopping chemotherapy. Methods: Eligible pts were those who progressed while receiving chemotherapy [docetaxel (D) or mitoxantrone (M)] or within 12 weeks from stopping it. Pts were then continued or resumed on their last chemotherapy with the addition of SOR at 400 mg PO BID. Pts were allowed a maximum of 6 cycles of chemotherapy +SOR followed by SOR as monotherapy until progression. Primary end point: Safety of SOR+ chemotherapy. Secondary end points: Toxicity, time to progression (TTP). And responses (biochemical and radiographic) Results: Twenty-two pts were enrolled; 21 evaluable (73% Gleason ≥ 7). Median age was 68 (59-83). Median PSA was 142 ng/dl (13.6-9,584). Median time from last chemotherapy to SOR was 4 weeks. Visceral and bone disease was present in 64%. D was given in 16 pts while M in 6. Ten pts (45%) showed biochemical response (18% with &gt;50% PSA decline). Despite progression before being on study, 16 pts (76%) achieved SD after starting SOR for a median duration of 6 months (4-12). The combination of SOR with either chemotherapy agent proved safe. Main grade 3/4 non-hematologic toxicities: Fatigue 7 (32%), 4 (18%) hand/foot syndrome, hypocalcemia and hyperglycemia in 2 pts (9%) each. Grade 3/4 leukopenia was seen in 7 (31%), neutropenia in 6 (27%), and thrombocytopenia in 2 (9%). Dose reduction of SOR occurred at least once in 15 pts (68%). Major reasons are hand/foot syndrome (22%), fatigue (22%), rash (13%), and neutropenia (9%). With a median follow-up of 19 months (3-46), 5 pts (23%) remain alive for a median OS of 8 months. TTP by PSA was 3 months (2-6) and TTP by imaging and/or clinically was 6 months (2-12). Median number of treatment cycles given was 6 (1-10). Conclusions: SOR can safely be combined with chemotherapy. SOR overcomes chemotherapy-resistance and shows biochemical and radiographic stability in this refractory pt population.
Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).
Authors: Alireza Eghtedar, Stefan Faderl, Hagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, Alessandra Ferrajoli, Tapan Kadia, Sherry A. Pierce, Jenny Shan, Jorge E. Cortes, Farhad Ravandi
Journal: Blood (2010)
Role of Venous Outflow Obstruction and Venous Valvular Incompetence as Mechanisms for Venous Stasis Syndrome Following Deep Vein Thrombosis: A Population-Based Cohort Study.
Authors: Aneel A. Ashrani, John A. Heit, Brian D. Lahr, Tanya M. Petterson, Kent R. Bailey
Journal: Blood (2006)
Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients
Authors: Dana E Rollison, Kenneth H. Shain, Ji-Hyun Lee, Shalaka S Hampras, William Fulp, Kate Fisher, Najla H Al Ali, Eric Padron, Jeffrey Lancet, Qiang Xu, Robert D. Knight, Alan F. List, William Dalton, Rami Komrokji
Journal: Blood (2014)
Increased Ratios of Internal Organ Volume to Body Mass in Chuvash Polycythemia and HIF-2α Repression of p21Cip Expression through C-MYC.
Authors: Donghoon Yoon, David Okhotin, Bumjun Kim, Yulia Okhotina, Daniel J Okhotin, Galina Y Miasnikova, Adelina I Sergueeva, Lydia A Polyakova, Alexei Maslow, Yonggu Lee, Gregg L Semenza, Josef T. Prchal, Victor R. Gordeuk
Journal: Blood (2009)
Multi-Drug Resistant Organisms Are Common in Fecal Surveillance Cultures and Do Not Predict Bacteremia but Correlate with Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplants
Authors: Vikram Mathews, Alok Srivastava, Biju George, Anu Korula, Susmitha Perumalla, Fouzia Nambiathayil Abubacker, Nisham P N, Anup Devasia, Aby Abraham, Veeraraghavan Balaji, Kavitha M Lakshmi
Journal: Blood (2016)
Antitumor Genotoxic Agents, Such as Fludarabine*, Doxorubincin or Cis-Platine, Induce Activation of STAT1 in a p53 Protein Dependent Manner.
Authors: Ibtissam Youlyouz-Marfak, Christophe Le Clorennec, Imen Najjar, Fanny Baran-Marszak, Nathalie Gachard, Liliane Remenieras, Arnaud Jaccard, Georg W. Bornkamm, Remi Fagard, Jean Feuillard
Journal: Blood (2005)
Comparison between Progenitor Cells from Mobilized Peripheral Blood (PB) in Healthy Donors and Non-Hodgkin’s Lymphoma (NHL) Patients.
Authors: Eva M. Villaron, Julia Almeida, Natalia Lopez-Holgado, Fermin M. Sanchez-Guijo, Mercedes Alberca, Belen Blanco, Luis I. Sanchez-Abarca, Olga Lopez, Jose A. Perez-Simon, Jesus F. San Miguel, Consuelo del Cañizo
Journal: Blood (2004)
A Phase I/II, National, Multicenter, Open Label Study of Bortezomib (Velcade) and Fludarabine, Cytarabine and Idarubicin (Flag-Ida) (V-Flag-Ida) in Pts with Relapsed and/or Refractory Acute Myeloblastic Leukemia (AML).
Authors: Maria-Victoria Mateos, Rafael Martínez, Salut Brunet, Maria-Belén Vidriales, Albert Oriol, Juan José Lahuerta, Mari Luz Amigo, Jordi Esteve, Javier de la Rubia, Luis Palomera, Javier Bueno, Jesus F San Miguel
Journal: Blood (2009)
PO17A NOVEL IMMUNOHISTOCHEMICAL METHODOLOGY FOR THE INVESTIGATION OF STEM CELL-LIKE SUBPOPULATIONS IN GLIOMA SPHEROIDS AND MIGRATORY CELLS
Authors: Vinton Cheng, Filomena Estevez, Aruna Chakrabarty, Julia Cockle, Susan Short, Anke Brüning-Richardson
Journal: Neuro-Oncology (2015)

INTRODUCTION: Targeting tumour invasion may represent a complementary treatment when added to standard care in highly infiltrating tumours such as glioblastomas. Invasiveness is believed to be related to stem cell-like qualities of distinct subpopulations of glioma cells. The characterisation of phenotypic differences between invading and non-invading cells will aid the development of specific anti-migratory drugs. A novel immunohistochemical approach was taken to phenotypically characterise invasive migratory glioma cells after drug treatment in a 3D spheroid invasion assay. METHOD: Spheroids generated from U87 and U251 cells were embedded in a collagen matrix and treated over 72 hours with the anti-migratory drugs LiCl and Bio-Indirubin. A protocol was established to prepare the collagen embedded spheroids and migratory cells for immunohistochemistry (IHC). Markers of proliferation, apoptosis and stemness were optimised for IHC. RESULTS: In both U87 and U251, protein expression profiles in cells maintained in the original core were distinct from profiles in migratory cells. The most striking change of expression was observed for SOX-2 in U251, where drug treatment led to a reduction of SOX-2 levels in core-maintained cells whereas migrating cells exhibited higher levels of SOX-2. We could also quantify drug-induced changes in proliferation and apoptotic events in spheroids generated from both cell lines using this method. CONCLUSION: A novel IHC protocol allowed the investigation of the invasive behaviour of cells in a 3D experimental model. Protein expression profiles of markers of stemness indicate that subpopulations of cells exist within glioma spheroids that may respond differently to anti-migratory drugs.
In Vitro and In Vivo Characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 Targeting NHL
Authors: Xing Zhao, Narendiran Rajasekaran, Uwe Reusch, Michael Weichel, Kristina Ellwanger, Jens-Peter Marschner, Martin Treder, Holbrook Kohrt
Journal: Blood (2015)
NHS hospitals must help patients quit smoking, says British Thoracic Society
Authors: Ingrid Torjesen
Journal: BMJ (2016)

NHS hospitals around the United Kingdom are not meeting national standards on helping patients to quit smoking and are not enforcing smoke-free premises, a report by the British Thoracic Society has found.1

For the report, smoking cessation and smoke-free policies and practices at 146 hospitals around the UK were reviewed from April to May 2016, including the records of 14 750 patients treated at the hospitals.

More than a quarter (27%) of hospital patients were not even asked whether they smoked, the report found. Of those that did smoke, 72% were not asked …